Search results
Q&A: This New CEO Has Big Ideas For A Small Biotech
Investor's Business Daily· 2 hours agoCatalyst Pharmaceuticals' (CPRX) new Chief Executive, Richard Daly, is no stranger to working at big companies. Catalyst is not a pharma giant. Former...
Novavax Stock Surges 140% on $1.4 Billion Deal With Sanofi
Barrons.com· 2 hours agoNovavax the pharmaceutical company that last year warned that falling sales of its Covid-19 vaccine...
Drug shortages: What to do when you can’t get your medicine
Deseret News via Yahoo News· 13 hours agoBut many insurance companies have on their drug formulary only the generic form. So all patients can...
French, US drug firms team up for Covid-flu shot
Medical Xpress· 3 hours agoFrench pharmaceutical giant Sanofi and struggling US rival Novavax announced Friday an alliance to sell a COVID vaccine and develop another that combines...
Q1 2024 Eton Pharmaceuticals Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 1 hour agoIt has been a very productive start to 2024 for the company, and we have a number of exciting items to discuss today, in addition to posting record revenue sales in Q1, but ...
Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences
FOX 4 Kansas City· 3 hours agoCitius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development ...
Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension
Pharmaceutical Technology via Yahoo Finance· 5 hours agoFormosa Pharmaceuticals president and CEO Erick Co stated: “We are pleased to...partnership with...
TFF Pharmaceuticals (NASDAQ:TFFP) vs. Alnylam Pharmaceuticals (NASDAQ:ALNY) Financial Contrast
ETF DAILY NEWS· 9 hours agoAlnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) and TFF Pharmaceuticals (NASDAQ:TFFP – Get Free Report) are both medical companies, but which is ...
Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target Increased to $60.00 by Analysts at Oppenheimer
ETF DAILY NEWS· 9 hours agoCorbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) had its target price upped by equities research analysts at Oppenheimer from $58.00 to $60.00 in a research report issued ...
5 weight-loss drug stocks to watch as Ozempic, Zepbound sales surge
Bankrate via AOL· 2 days agocompany also reported sales growth of 36 percent in 2023. Novo’s market value is now greater than...
